A Phase 1 interventional study of [14C]-LOXO-305 and LOXO-305 in Healthy, sponsored by Eli Lilly and Company. Completed at 1 site in United States. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-01-13.
Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The main purpose of this study is to evaluate the absorption, metabolism, and excretion (AME) profiles of pirtobrutinib (LOXO-305), to identify and characterize metabolites of pirtobrutinib (LOXO-305), and to assess the safety and tolerability of [14C] LOXO-305 in Part 1. To determine the absolute bioavailability of pirtobrutinib (LOXO-305), to evaluate the plasma concentration of total radioactivity, to evaluate the urinary excretion of [14C] LOXO-305 and total radioactivity, to evaluate the fecal excretion of [14C] LOXO-305 and total radioactivity, and to assess the safety and tolerability of pirtobrutinib (LOXO-305), and [14C] LOXO-305 in Part 2. Blood tests will be performed to check how much pirtobrutinib (LOXO-305) and [14C] LOXO-305 gets into the bloodstream and how long it takes the body to eliminate it.
The study will last up to approximately 60 days for Part 1 and approximately 47 days for Part 2.
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received a single dose of 200 milligram (mg) LOXO-305 radiolabelled with carbon-14, i.e., \[14C\]-LOXO-305 (approximately 200 microcurie radioactivity) administered as an oral solution.
Drug: [14C]-LOXO-305
Participants received: a single dose of 200 mg LOXO-305 administered as 2×100 mg oral tablets followed 2 hours later by a single dose of less than 100 microgram (μg) of \[14C\]-LOXO-305 (approximately 1 microcurie radioactivity) administered as an intravenous (IV) push over approximately 2 minutes.
Drug: LOXO-305 · Drug: [14C]-LOXO-305
Administered orally
Also known as: LY3527727
Administered orally
Also known as: Pirtobrutinib, LY3527727
Administered IV
Also known as: LY3527727
Part 1: Pharmacokinetics (PK): Area Under the Concentration-time Curve From Time 0 Extrapolated to Infinity (AUC0-inf) of LOXO-305 in Plasma Following a Single Oral Dose of [14C]-LOXO-305
AUC0-inf of LOXO-305 in plasma.
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360 hours post-dose
Part 1: PK: Area Under the Concentration-time Curve From Time 0 Extrapolated to Infinity (AUC0-inf) of Total Radioactivity in Plasma and Whole Blood Following a Single Oral Dose of [14C]-LOXO-305
AUC0-inf of total radioactivity in plasma and whole blood.
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360 hours post-dose
Part 1: PK: Area Under the Concentration-time Curve From Hour 0 to the Last Measurable Concentration (AUC0-t) of LOXO-305 in Plasma Following a Single Oral Dose of [14C]-LOXO-305
AUC0-t of LOXO-305 in plasma.
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360 hours post-dose
Part 1: PK: Area Under the Concentration-time Curve From Hour 0 to the Last Measurable Concentration (AUC0-t) of Total Radioactivity in Plasma and Whole Blood Following a Single Oral Dose of [14C]-LOXO-305
AUC0-t of total radioactivity in plasma and whole blood.
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360 hours post-dose
Part 1: PK: Maximum Observed Plasma Concentration (Cmax) of LOXO-305 in Plasma Following a Single Oral Dose of [14C]-LOXO-305
Cmax of LOXO-305 in plasma.
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360 hours post-dose
Part 1: PK: Maximum Observed Plasma Concentration (Cmax) of Total Radioactivity in Plasma and Whole Blood Following a Single Oral Dose of [14C]-LOXO-305
Cmax of total radioactivity in plasma and whole blood.
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360 hours post-dose
Part 1: PK: Time to Maximum Observed Concentration (Tmax) of LOXO-305 in Plasma Following a Single Oral Dose of [14C]-LOXO-305
Tmax of LOXO-305 in plasma.
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360 hours post-dose
Part 1: PK: Time to Maximum Observed Concentration (Tmax) of Total Radioactivity in Plasma and Whole Blood Following a Single Oral Dose of [14C]-LOXO-305
Tmax of total radioactivity in plasma and whole blood.
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360 hours post-dose
Part 1: PK: Apparent Terminal Elimination Half-life (t1/2) of LOXO-305 in Plasma Following a Single Oral Dose of [14C]-LOXO-305
t1/2 of LOXO-305 in plasma.
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360 hours post-dose
Part 1: PK: Apparent Terminal Elimination Half-life (t1/2) of Total Radioactivity in Plasma and Whole Blood Following a Single Oral Dose of [14C]-LOXO-305
t1/2 of total radioactivity in plasma and whole blood.
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360 hours post-dose
Part 1: PK: Apparent Systemic Clearance (CL/F) of LOXO-305 in Plasma Following a Single Oral Dose of [14C]-LOXO-305
CL/F of LOXO-305 in plasma.
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360 hours post-dose
Part 1: PK: Apparent Volume of Distribution (Vz/F) of LOXO-305 in Plasma Following a Single Oral Dose of [14C]-LOXO-305
Vz/F of LOXO-305 in plasma.
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360 hours post-dose
Part 1: PK: Ratio of AUC0-inf of Plasma LOXO-305 to AUC0-inf of Plasma Total Radioactivity
AUC0-inf of plasma LOXO-305 relative to AUC0-inf of plasma total radioactivity, expressed in ratio.
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360 hours post-dose
Part 1: PK: Ratio of AUC0-inf of Whole Blood Total Radioactivity to AUC0-inf of Plasma Total Radioactivity
AUC0-inf of whole blood total radioactivity relative to AUC0-inf of plasma total radioactivity, expressed in ratio.
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360 hours post-dose
Part 1: PK: Cumulative Amount of Total Radioactivity Excreted in Urine
The urine sampling time points from pre-dose through 360 hours post-dose were used to assess this outcome.
Time frame: Pre-dose, 0 (time of dose), 6, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360 hours post-dose
Part 1: PK: Cumulative Amount of Total Radioactivity Excreted in Feces
The feces sampling time points from the 0 hour (i.e. time of dose) through 360 hours post-dose were used to assess this outcome.
Time frame: 0 (time of dose), 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360 hours post-dose
Part 1: PK: Mean Cumulative Percentage of Total Radioactivity Excreted in Feces
The feces sampling time points from the 0 hour (i.e. time of dose) through 360 hours post-dose were used to assess this outcome.
Time frame: 0 (time of dose), 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360 hours post-dose
Part 1: PK: Mean Cumulative Percentage of Total Radioactivity Excreted in Urine
The urine sampling time points from pre-dose through 360 hours post-dose were used to assess this outcome.
Time frame: Pre-dose, 0 (time of dose), 6, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360 hours post-dose
Part 1: PK: Metabolic Profile of LOXO-305 in Plasma Following a Single Oral Dose of [14C]-LOXO-305
The metabolic profile of LOXO-305 following a single oral dose of \[14C\]-LOXO-305 was done to assess the presence of LOXO-305 and various metabolites (M1 to M4, M11, M12, M15 to M22) in plasma using high-performance liquid chromatography with radiochemical detection. Metabolites are identified by comparison with known standards (when available) and/or by liquid chromatography/tandem mass spectrometry analysis. The presence of any metabolite in a given matrix is indicated as '1' and absence from that matrix is indicated as '0'.
Time frame: 1, 2, 4, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264 h post-dose
Part 1: PK: Metabolic Profile of LOXO-305 in Urine Following a Single Oral Dose of [14C]-LOXO-305
The metabolic profile of LOXO-305 following a single oral dose of \[14C\]-LOXO-305 was done to assess the presence of LOXO-305 and various metabolites (M1 to M4, M11, M12, M15 to M22) in urine using high-performance liquid chromatography with radiochemical detection. Metabolites are identified by comparison with known standards (when available) and/or by liquid chromatography/tandem mass spectrometry analysis. The presence of any metabolite in a given matrix is indicated as '1' and absence from that matrix is indicated as '0'.
Time frame: Pre-dose, 0 (time of dose), 6, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360 hours post-dose
Part 1: PK: Metabolic Profile of LOXO-305 in Feces Following a Single Oral Dose of [14C]-LOXO-305
The metabolic profile of LOXO-305 following a single oral dose of \[14C\]-LOXO-305 was done to assess the presence of LOXO-305 and various metabolites (M1 to M4, M11, M12, M15 to M22) in feces using high-performance liquid chromatography with radiochemical detection. Metabolites are identified by comparison with known standards (when available) and/or by liquid chromatography/tandem mass spectrometry analysis. The presence of any metabolite in a given matrix is indicated as '1' and absence from that matrix is indicated as '0'.
Time frame: 0 (time of dose), 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360 hours post-dose
Part 2: PK: Area Under the Concentration-time Curve From Time 0 Extrapolated to Infinity (AUC0-inf) of LOXO-305 in Plasma
AUC0-inf of LOXO-305 in plasma. The sampling time points from pre-oral dose through 192 hours post-IV dose were used to assess this outcome.
Time frame: Pre-oral dose, 0.5, 1, 2 hours post oral dose, 0.03, 0.17, 0.33, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192 hours post IV dose.
Part 2: PK: Area Under the Concentration-time Curve From Time 0 Extrapolated to Infinity (AUC0-inf) of [14C]-LOXO-305 in Plasma
AUC0-inf of \[14C\]-LOXO-305 in plasma. The sampling time points from pre-IV dose through 192 hours post-IV dose were used to assess this outcome.
Time frame: Pre-IV dose, 0.03, 0.17, 0.33, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192 hours post IV dose.
Part 2: PK: Area Under the Concentration-time Curve From Time 0 Extrapolated to Infinity (AUC0-inf) of Total Radioactivity in Plasma
AUC0-inf of total radioactivity in plasma. The sampling time points from pre-IV dose through 192 hours post-IV dose were used to assess this outcome.
Time frame: Pre-IV dose, 0.03, 0.17, 0.33, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192 hours post IV dose.
Part 2: PK: Area Under the Concentration-time Curve From Hour 0 to the Last Measurable Concentration (AUC0-t) of LOXO-305 in Plasma
AUC0-t of LOXO-305 in plasma. The sampling time points from pre-oral dose through 192 hours post-IV dose were used to assess this outcome.
Time frame: Pre-oral dose, 0.5, 1, 2 hours post oral dose, 0.03, 0.17, 0.33, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192 hours post IV dose
Part 2: PK: Area Under the Concentration-time Curve From Hour 0 to the Last Measurable Concentration (AUC0-t) of [14C]-LOXO-305 in Plasma
AUC0-t of \[14C\]-LOXO-305 in plasma. The sampling time points from pre-IV dose through 192 hours post-IV dose were used to assess this outcome.
Time frame: Pre-IV dose, 0.03, 0.17, 0.33, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192 hours post IV dose.
Part 2: PK: Area Under the Concentration-time Curve From Hour 0 to the Last Measurable Concentration (AUC0-t) of Total Radioactivity in Plasma
AUC0-t of Total Radioactivity in Plasma. The sampling time points from pre-IV dose through 192 hours post-IV dose were used to assess this outcome.
Time frame: Pre-IV dose, 0.03, 0.17, 0.33, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192 hours post IV dose.
Part 2: PK: Maximum Observed Plasma Concentration (Cmax) of LOXO-305 in Plasma
Cmax of LOXO-305 in plasma. The sampling time points from pre-oral dose through 192 hours post-IV dose were used to assess this outcome.
Time frame: Pre-oral dose, 0.5, 1, 2 hours post oral dose, 0.03, 0.17, 0.33, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192 hours post IV dose
Part 2: PK: Maximum Observed Plasma Concentration (Cmax) of [14C]-LOXO-305 in Plasma
Cmax of \[14C\]-LOXO-305 in plasma. The sampling time points from pre-IV dose through 192 hours post-IV dose were used to assess this outcome.
Time frame: Pre-IV dose, 0.03, 0.17, 0.33, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192 hours post IV dose.
Part 2: PK: Maximum Observed Plasma Concentration (Cmax) of Total Radioactivity in Plasma
Cmax of Total Radioactivity in Plasma. The sampling time points from pre-IV dose through 192 hours post-IV dose were used to assess this outcome.
Time frame: Pre-IV dose, 0.03, 0.17, 0.33, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192 hours post IV dose.
Part 2: PK: Time to Maximum Observed Concentration (Tmax) of LOXO-305 in Plasma
Tmax of LOXO-305 in plasma. The sampling time points from pre-oral dose through 192 hours post-IV dose were used to assess this outcome.
Time frame: Pre-oral dose, 0.5, 1, 2 hours post oral dose, 0.03, 0.17, 0.33, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192 hours post IV dose
Part 2: PK: Time to Maximum Observed Concentration (Tmax) of [14C]-LOXO-305 in Plasma
Tmax of \[14C\]-LOXO-305 in plasma. The sampling time points from pre-IV dose through 192 hours post-IV dose were used to assess this outcome.
Time frame: Pre-IV dose, 0.03, 0.17, 0.33, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192 hours post IV dose.
Part 2: PK: Time to Maximum Observed Concentration (Tmax) of Total Radioactivity in Plasma
Tmax of Total Radioactivity in plasma. The sampling time points from pre-IV dose through 192 hours post-IV dose were used to assess this outcome.
Time frame: Pre-IV dose, 0.03, 0.17, 0.33, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192 hours post IV dose.
Part 2: PK: Apparent Terminal Elimination Half-life (t1/2) of LOXO-305 in Plasma
t1/2 of LOXO-305 in plasma. The sampling time points from pre-oral dose through 192 hours post-IV dose were used to assess this outcome.
Time frame: Pre-oral dose, 0.5, 1, 2 hours post oral dose, 0.03, 0.17, 0.33, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192 hours post IV dose
Part 2: PK: Apparent Terminal Elimination Half-life (t1/2) of [14C]-LOXO-305 in Plasma
t1/2 of \[14C\]-LOXO-305 in plasma. The sampling time points from pre-IV dose through 192 hours post-IV dose were used to assess this outcome.
Time frame: Pre-IV dose, 0.03, 0.17, 0.33, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192 hours post IV dose.
Part 2: PK: Apparent Terminal Elimination Half-life (t1/2) of Total Radioactivity in Plasma
t1/2 of Total Radioactivity in plasma. The sampling time points from pre-IV dose through 192 hours post-IV dose were used to assess this outcome.
Time frame: Pre-IV dose, 0.03, 0.17, 0.33, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192 hours post IV dose.
Part 2: PK: Apparent Systemic Clearance (CL/F) of LOXO-305 in Plasma
CL/F of LOXO-305 in plasma. The sampling time points from pre-oral dose through 192 hours post-IV dose were used to assess this outcome.
Time frame: Pre-oral dose, 0.5, 1, 2 hours post oral dose, 0.03, 0.17, 0.33, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192 hours post IV dose
Part 2: PK: Apparent Volume of Distribution During the Terminal Phase (Vz/F) of LOXO-305 in Plasma
Vz/F of LOXO-305 in plasma. The sampling time points from pre-oral dose through 192 hours post-IV dose were used to assess this outcome.
Time frame: Pre-oral dose, 0.5, 1, 2 hours post oral dose, 0.03, 0.17, 0.33, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192 hours post IV dose
Part 2: PK: Absolute Bioavailability of LOXO-305 in Plasma
The absolute bioavailability expressed in ratio was calculated using the formula= AUC0-inf (oral) x Dose (IV) divided by AUC0-inf (IV) x Dose (oral) . The sampling time points from pre-oral dose through 192 hours post-IV dose were used to assess this outcome.
Time frame: Pre-oral dose, 0.5, 1, 2 hours post oral dose, 0.03, 0.17, 0.33, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192 hours post IV dose
Part 2: PK: Total Clearance (CL) of [14C]-LOXO-305 in Plasma
CL of \[14C\]-LOXO-305 in plasma. The sampling time points from pre-IV dose through 192 hours post-IV dose were used to assess this outcome.
Time frame: Pre-IV dose, 0.03, 0.17, 0.33, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192 hours post IV dose.
Part 2: PK: Volume of Distribution (Vz) of [14C]-LOXO-305 in Plasma
Vz of \[14C\]-LOXO-305 in plasma. The sampling time points from pre-IV dose through 192 hours post-IV dose were used to assess this outcome.
Time frame: Pre-IV dose, 0.03, 0.17, 0.33, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192 hours post IV dose.
Part 2: PK: Volume of Distribution at Steady State (Vss) of [14C]-LOXO-305 in Plasma
Vss of \[14C\]-LOXO-305 in plasma. The sampling time points from pre-IV dose through 192 hours post-IV dose were used to assess this outcome.
Time frame: Pre-IV dose, 0.03, 0.17, 0.33, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192 hours post IV dose
Part 2: PK: Renal Clearance (CLR) of [14C]-LOXO-305
CLR of \[14C\]-LOXO-305 in urine collection. The urine sampling time points from pre-IV dose through 192 hours post-IV dose were used to assess this outcome.
Time frame: Pre-IV dose, 4, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192 hours post IV dose
Part 2: PK: Cumulative Amount of [14C]-LOXO-305 Excreted in Urine
The urine sampling time points from pre-oral dose through 192 hours post-IV dose were used to assess this outcome.
Time frame: Pre-oral dose, 0 (time of oral dose), 4, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192 hours post IV dose
Part 2: PK: Cumulative Amount of Total Radioactivity Excreted in Urine
The urine sampling time points from pre-oral dose through 192 hours post-IV dose were used to assess this outcome.
Time frame: Pre-oral dose, 0 (time of oral dose), 4, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192 hours post IV dose
Part 2: PK: Cumulative Amount of [14C]-LOXO-305 Excreted in Feces
The Feces sampling time points from the 0 hour (i.e. time of oral dose) through 192 hours post-IV dose were used to assess this outcome.
Time frame: 0 (time of oral dose), 12, 24, 48, 72, 96, 120, 144, 168, 192 hours post IV dose
Part 2: PK: Cumulative Amount of Total Radioactivity Excreted in Feces
The Feces sampling time points from the 0 hour (i.e. time of oral dose) through 192 hours post-IV dose were used to assess this outcome.
Time frame: 0 (time of oral dose), 12, 24, 48, 72, 96, 120, 144, 168, 192 hours post IV dose
Part 2: PK: Mean Cumulative Percentage of [14C]-LOXO-305 Excreted in Urine
The urine sampling time points from pre-oral dose through 192 hours post-IV dose were used to assess this outcome.
Time frame: Pre-oral dose, 0 (time of oral dose), 4, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192 hours post IV dose
Part 2: PK: Mean Cumulative Percentage of Total Radioactivity Excreted in Urine
The urine sampling time points from pre-oral dose through 192 hours post-IV dose were used to assess this outcome.
Time frame: Pre-oral dose, 0 (time of oral dose), 4, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192 hours post IV dose
Part 2: PK: Mean Cumulative Percentage of [14C]-LOXO-305 Excreted in Feces
The Feces sampling time points from the 0 hour (i.e. time of oral dose) through 192 hours post-IV dose were used to assess this outcome.
Time frame: 0 (time of oral dose), 12, 24, 48, 72, 96, 120, 144, 168, 192 hours post IV dose
Part 2: PK: Mean Cumulative Percentage of Total Radioactivity Excreted in Feces
The Feces sampling time points from the 0 hour (i.e. time of oral dose) through 192 hours post-IV dose were used to assess this outcome.
Time frame: 0 (time of oral dose), 12, 24, 48, 72, 96, 120, 144, 168, 192 hours post IV dose
| Milestone | Part 1: [14C]-LOXO-305 Oral Solution | Part 2: LOXO-305 Oral Tablet + [14C]-LOXO-305 IV Solution |
|---|---|---|
| Started | 4 | 5 |
| Received at least one dose of study drug. | 4 | 5 |
| Completed | 4 | 5 |
| Not completed | 0 | 0 |
AUC0-inf of LOXO-305 in plasma.
| hours*nanogram per milliliter (h*ng/mL) | Part 1: [14C]-LOXO-305 Oral Solution |
|---|---|
| Part 1: Pharmacokinetics (PK): Area Under the Concentration-time Curve From Time 0 Extrapolated to Infinity (AUC0-inf) of LOXO-305 in Plasma Following a Single Oral Dose of [14C]-LOXO-305 | 75300 ± 14.8 |
AUC0-inf of total radioactivity in plasma and whole blood.
| hours*nanogram equivalent per gram | Part 1: [14C]-LOXO-305 Oral Solution |
|---|---|
| Plasma | 111000 ± 15.8 |
| Whole Blood | 71200 ± 12.6 |
AUC0-t of LOXO-305 in plasma.
| hours*nanogram per milliliter (h*ng/mL) | Part 1: [14C]-LOXO-305 Oral Solution |
|---|---|
| Part 1: PK: Area Under the Concentration-time Curve From Hour 0 to the Last Measurable Concentration (AUC0-t) of LOXO-305 in Plasma Following a Single Oral Dose of [14C]-LOXO-305 | 74500 ± 14.9 |
AUC0-t of total radioactivity in plasma and whole blood.
| hours*nanogram equivalent per gram | Part 1: [14C]-LOXO-305 Oral Solution |
|---|---|
| Plasma | 109000 ± 16.1 |
| Whole Blood | 68900 ± 13 |
Cmax of LOXO-305 in plasma.
| nanograms per milliliter (ng/mL) | Part 1: [14C]-LOXO-305 Oral Solution |
|---|---|
| Part 1: PK: Maximum Observed Plasma Concentration (Cmax) of LOXO-305 in Plasma Following a Single Oral Dose of [14C]-LOXO-305 | 3530 ± 8.8 |
Cmax of total radioactivity in plasma and whole blood.
| nanogram equivalent per gram | Part 1: [14C]-LOXO-305 Oral Solution |
|---|---|
| Plasma | 4280 ± 7.7 |
| Whole Blood | 3020 ± 7.7 |
Tmax of LOXO-305 in plasma.
| hours | Part 1: [14C]-LOXO-305 Oral Solution |
|---|---|
| Part 1: PK: Time to Maximum Observed Concentration (Tmax) of LOXO-305 in Plasma Following a Single Oral Dose of [14C]-LOXO-305 | 1.80 (1.5 to 3) |
Tmax of total radioactivity in plasma and whole blood.
| hours | Part 1: [14C]-LOXO-305 Oral Solution |
|---|---|
| Plasma | 1.80 (1.50 to 4) |
| Whole Blood | 1.80 (1.50 to 3) |
t1/2 of LOXO-305 in plasma.
| hours | Part 1: [14C]-LOXO-305 Oral Solution |
|---|---|
| Part 1: PK: Apparent Terminal Elimination Half-life (t1/2) of LOXO-305 in Plasma Following a Single Oral Dose of [14C]-LOXO-305 | 17.8 ± 2.26 |
t1/2 of total radioactivity in plasma and whole blood.
| hours | Part 1: [14C]-LOXO-305 Oral Solution |
|---|---|
| Plasma | 25.3 ± 4.76 |
| Whole Blood | 21.7 ± 3.08 |
CL/F of LOXO-305 in plasma.
| liter per hour (L/h) | Part 1: [14C]-LOXO-305 Oral Solution |
|---|---|
| Part 1: PK: Apparent Systemic Clearance (CL/F) of LOXO-305 in Plasma Following a Single Oral Dose of [14C]-LOXO-305 | 2.69 ± 15.8 |
Vz/F of LOXO-305 in plasma.
| liter (L) | Part 1: [14C]-LOXO-305 Oral Solution |
|---|---|
| Part 1: PK: Apparent Volume of Distribution (Vz/F) of LOXO-305 in Plasma Following a Single Oral Dose of [14C]-LOXO-305 | 68.8 ± 21 |
AUC0-inf of plasma LOXO-305 relative to AUC0-inf of plasma total radioactivity, expressed in ratio.
| ratio | Part 1: [14C]-LOXO-305 Oral Solution |
|---|---|
| Part 1: PK: Ratio of AUC0-inf of Plasma LOXO-305 to AUC0-inf of Plasma Total Radioactivity | 0.680 ± 1.2 |
AUC0-inf of whole blood total radioactivity relative to AUC0-inf of plasma total radioactivity, expressed in ratio.
| ratio | Part 1: [14C]-LOXO-305 Oral Solution |
|---|---|
| Part 1: PK: Ratio of AUC0-inf of Whole Blood Total Radioactivity to AUC0-inf of Plasma Total Radioactivity | 0.642 ± 3.4 |
The urine sampling time points from pre-dose through 360 hours post-dose were used to assess this outcome.
| milligram equivalent (mg eq) | Part 1: [14C]-LOXO-305 Oral Solution |
|---|---|
| Part 1: PK: Cumulative Amount of Total Radioactivity Excreted in Urine | 116 ± 4.05 |
The feces sampling time points from the 0 hour (i.e. time of dose) through 360 hours post-dose were used to assess this outcome.
| milligram equivalent (mg eq) | Part 1: [14C]-LOXO-305 Oral Solution |
|---|---|
| Part 1: PK: Cumulative Amount of Total Radioactivity Excreted in Feces | 75.5 ± 5.29 |
The feces sampling time points from the 0 hour (i.e. time of dose) through 360 hours post-dose were used to assess this outcome.
| percentage of total radioactivity | Part 1: [14C]-LOXO-305 Oral Solution |
|---|---|
| Part 1: PK: Mean Cumulative Percentage of Total Radioactivity Excreted in Feces | 37.3 ± 2.31 |
The urine sampling time points from pre-dose through 360 hours post-dose were used to assess this outcome.
| percentage of total radioactivity | Part 1: [14C]-LOXO-305 Oral Solution |
|---|---|
| Part 1: PK: Mean Cumulative Percentage of Total Radioactivity Excreted in Urine | 57 ± 2.16 |
The metabolic profile of LOXO-305 following a single oral dose of \[14C\]-LOXO-305 was done to assess the presence of LOXO-305 and various metabolites (M1 to M4, M11, M12, M15 to M22) in plasma using high-performance liquid chromatography with radiochemical detection. Metabolites are identified by comparison with known standards (when available) and/or by liquid chromatography/tandem mass spectrometry analysis. The presence of any metabolite in a given matrix is indicated as '1' and absence from that matrix is indicated as '0'.
| sample positive | Part 1: [14C]-LOXO-305 Oral Solution |
|---|---|
| Loxo-305 | 1 |
| M1 | 1 |
| M2 | 1 |
| M3 | 0 |
| M4 | 1 |
| M11 | 0 |
| M12 | 0 |
| M15 | 0 |
| M16 | 0 |
| M17 | 0 |
| M18 | 0 |
| M19 | 0 |
| M20 | 0 |
| M21 | 0 |
| M22 | 0 |
The metabolic profile of LOXO-305 following a single oral dose of \[14C\]-LOXO-305 was done to assess the presence of LOXO-305 and various metabolites (M1 to M4, M11, M12, M15 to M22) in urine using high-performance liquid chromatography with radiochemical detection. Metabolites are identified by comparison with known standards (when available) and/or by liquid chromatography/tandem mass spectrometry analysis. The presence of any metabolite in a given matrix is indicated as '1' and absence from that matrix is indicated as '0'.
| sample positive | Part 1: [14C]-LOXO-305 Oral Solution |
|---|---|
| Loxo-305 | 1 |
| M1 | 0 |
| M2 | 1 |
| M3 | 1 |
| M4 | 1 |
| M11 | 0 |
| M12 | 1 |
| M15 | 1 |
| M16 | 1 |
| M17 | 1 |
| M18 | 1 |
| M19 | 1 |
| M20 | 0 |
| M21 | 0 |
| M22 | 0 |
The metabolic profile of LOXO-305 following a single oral dose of \[14C\]-LOXO-305 was done to assess the presence of LOXO-305 and various metabolites (M1 to M4, M11, M12, M15 to M22) in feces using high-performance liquid chromatography with radiochemical detection. Metabolites are identified by comparison with known standards (when available) and/or by liquid chromatography/tandem mass spectrometry analysis. The presence of any metabolite in a given matrix is indicated as '1' and absence from that matrix is indicated as '0'.
| sample positive | Part 1: [14C]-LOXO-305 Oral Solution |
|---|---|
| Loxo-305 | 1 |
| M1 | 0 |
| M2 | 0 |
| M3 | 0 |
| M4 | 0 |
| M11 | 1 |
| M12 | 0 |
| M15 | 0 |
| M16 | 1 |
| M17 | 0 |
| M18 | 0 |
| M19 | 0 |
| M20 | 1 |
| M21 | 1 |
| M22 | 1 |
AUC0-inf of LOXO-305 in plasma. The sampling time points from pre-oral dose through 192 hours post-IV dose were used to assess this outcome.
| hours*nanogram per milliliter (h*ng/mL) | Part 2: LOXO-305 Oral Tablet + [14C]-LOXO-305 IV Solution |
|---|---|
| Part 2: PK: Area Under the Concentration-time Curve From Time 0 Extrapolated to Infinity (AUC0-inf) of LOXO-305 in Plasma | 105000 ± 28.1 |
AUC0-inf of \[14C\]-LOXO-305 in plasma. The sampling time points from pre-IV dose through 192 hours post-IV dose were used to assess this outcome.
| hours*picogram per milliliter | Part 2: LOXO-305 Oral Tablet + [14C]-LOXO-305 IV Solution |
|---|---|
| Part 2: PK: Area Under the Concentration-time Curve From Time 0 Extrapolated to Infinity (AUC0-inf) of [14C]-LOXO-305 in Plasma | 13700 ± 29 |
AUC0-inf of total radioactivity in plasma. The sampling time points from pre-IV dose through 192 hours post-IV dose were used to assess this outcome.
| hours*picogram equivalent per milliliter | Part 2: LOXO-305 Oral Tablet + [14C]-LOXO-305 IV Solution |
|---|---|
| Part 2: PK: Area Under the Concentration-time Curve From Time 0 Extrapolated to Infinity (AUC0-inf) of Total Radioactivity in Plasma | 18300 ± 25.2 |
AUC0-t of LOXO-305 in plasma. The sampling time points from pre-oral dose through 192 hours post-IV dose were used to assess this outcome.
| hours*nanogram per milliliter (h*ng/mL) | Part 2: LOXO-305 Oral Tablet + [14C]-LOXO-305 IV Solution |
|---|---|
| Part 2: PK: Area Under the Concentration-time Curve From Hour 0 to the Last Measurable Concentration (AUC0-t) of LOXO-305 in Plasma | 104000 ± 28.7 |
AUC0-t of \[14C\]-LOXO-305 in plasma. The sampling time points from pre-IV dose through 192 hours post-IV dose were used to assess this outcome.
| hours*picogram per milliliter | Part 2: LOXO-305 Oral Tablet + [14C]-LOXO-305 IV Solution |
|---|---|
| Part 2: PK: Area Under the Concentration-time Curve From Hour 0 to the Last Measurable Concentration (AUC0-t) of [14C]-LOXO-305 in Plasma | 13700 ± 29.2 |
AUC0-t of Total Radioactivity in Plasma. The sampling time points from pre-IV dose through 192 hours post-IV dose were used to assess this outcome.
| hours*picogram equivalent per milliliter | Part 2: LOXO-305 Oral Tablet + [14C]-LOXO-305 IV Solution |
|---|---|
| Part 2: PK: Area Under the Concentration-time Curve From Hour 0 to the Last Measurable Concentration (AUC0-t) of Total Radioactivity in Plasma | 18000 ± 25.8 |
Cmax of LOXO-305 in plasma. The sampling time points from pre-oral dose through 192 hours post-IV dose were used to assess this outcome.
| nanograms per milliliter (ng/mL) | Part 2: LOXO-305 Oral Tablet + [14C]-LOXO-305 IV Solution |
|---|---|
| Part 2: PK: Maximum Observed Plasma Concentration (Cmax) of LOXO-305 in Plasma | 4490 ± 19.2 |
Cmax of \[14C\]-LOXO-305 in plasma. The sampling time points from pre-IV dose through 192 hours post-IV dose were used to assess this outcome.
| picogram per milliliter (pg/mL) | Part 2: LOXO-305 Oral Tablet + [14C]-LOXO-305 IV Solution |
|---|---|
| Part 2: PK: Maximum Observed Plasma Concentration (Cmax) of [14C]-LOXO-305 in Plasma | 994 ± 31.6 |
Cmax of Total Radioactivity in Plasma. The sampling time points from pre-IV dose through 192 hours post-IV dose were used to assess this outcome.
| picogram equivalent per milliliter | Part 2: LOXO-305 Oral Tablet + [14C]-LOXO-305 IV Solution |
|---|---|
| Part 2: PK: Maximum Observed Plasma Concentration (Cmax) of Total Radioactivity in Plasma | 1110 ± 53.1 |
Tmax of LOXO-305 in plasma. The sampling time points from pre-oral dose through 192 hours post-IV dose were used to assess this outcome.
| hours | Part 2: LOXO-305 Oral Tablet + [14C]-LOXO-305 IV Solution |
|---|---|
| Part 2: PK: Time to Maximum Observed Concentration (Tmax) of LOXO-305 in Plasma | 5.00 (2.03 to 5) |
Tmax of \[14C\]-LOXO-305 in plasma. The sampling time points from pre-IV dose through 192 hours post-IV dose were used to assess this outcome.
| hours | Part 2: LOXO-305 Oral Tablet + [14C]-LOXO-305 IV Solution |
|---|---|
| Part 2: PK: Time to Maximum Observed Concentration (Tmax) of [14C]-LOXO-305 in Plasma | 0.167 (0.0333 to 12) |
Tmax of Total Radioactivity in plasma. The sampling time points from pre-IV dose through 192 hours post-IV dose were used to assess this outcome.
| hours | Part 2: LOXO-305 Oral Tablet + [14C]-LOXO-305 IV Solution |
|---|---|
| Part 2: PK: Time to Maximum Observed Concentration (Tmax) of Total Radioactivity in Plasma | 0.167 (0.0333 to 0.167) |
t1/2 of LOXO-305 in plasma. The sampling time points from pre-oral dose through 192 hours post-IV dose were used to assess this outcome.
| hours | Part 2: LOXO-305 Oral Tablet + [14C]-LOXO-305 IV Solution |
|---|---|
| Part 2: PK: Apparent Terminal Elimination Half-life (t1/2) of LOXO-305 in Plasma | 18.7 ± 1.68 |
t1/2 of \[14C\]-LOXO-305 in plasma. The sampling time points from pre-IV dose through 192 hours post-IV dose were used to assess this outcome.
| hours | Part 2: LOXO-305 Oral Tablet + [14C]-LOXO-305 IV Solution |
|---|---|
| Part 2: PK: Apparent Terminal Elimination Half-life (t1/2) of [14C]-LOXO-305 in Plasma | 17.6 ± 1.24 |
t1/2 of Total Radioactivity in plasma. The sampling time points from pre-IV dose through 192 hours post-IV dose were used to assess this outcome.
| hours | Part 2: LOXO-305 Oral Tablet + [14C]-LOXO-305 IV Solution |
|---|---|
| Part 2: PK: Apparent Terminal Elimination Half-life (t1/2) of Total Radioactivity in Plasma | 37.4 ± 9.72 |
CL/F of LOXO-305 in plasma. The sampling time points from pre-oral dose through 192 hours post-IV dose were used to assess this outcome.
| liter per hour (L/h) | Part 2: LOXO-305 Oral Tablet + [14C]-LOXO-305 IV Solution |
|---|---|
| Part 2: PK: Apparent Systemic Clearance (CL/F) of LOXO-305 in Plasma | 1.90 ± 28.1 |
Vz/F of LOXO-305 in plasma. The sampling time points from pre-oral dose through 192 hours post-IV dose were used to assess this outcome.
| liter (L) | Part 2: LOXO-305 Oral Tablet + [14C]-LOXO-305 IV Solution |
|---|---|
| Part 2: PK: Apparent Volume of Distribution During the Terminal Phase (Vz/F) of LOXO-305 in Plasma | 51.0 ± 23.6 |
The absolute bioavailability expressed in ratio was calculated using the formula= AUC0-inf (oral) x Dose (IV) divided by AUC0-inf (IV) x Dose (oral) . The sampling time points from pre-oral dose through 192 hours post-IV dose were used to assess this outcome.
| ratio | Part 2: LOXO-305 Oral Tablet + [14C]-LOXO-305 IV Solution |
|---|---|
| Part 2: PK: Absolute Bioavailability of LOXO-305 in Plasma | 0.855 ± 7.2 |
CL of \[14C\]-LOXO-305 in plasma. The sampling time points from pre-IV dose through 192 hours post-IV dose were used to assess this outcome.
| liter per hour (L/h) | Part 2: LOXO-305 Oral Tablet + [14C]-LOXO-305 IV Solution |
|---|---|
| Part 2: PK: Total Clearance (CL) of [14C]-LOXO-305 in Plasma | 1.63 ± 29.7 |
Vz of \[14C\]-LOXO-305 in plasma. The sampling time points from pre-IV dose through 192 hours post-IV dose were used to assess this outcome.
| liter (L) | Part 2: LOXO-305 Oral Tablet + [14C]-LOXO-305 IV Solution |
|---|---|
| Part 2: PK: Volume of Distribution (Vz) of [14C]-LOXO-305 in Plasma | 41.2 ± 29 |
Vss of \[14C\]-LOXO-305 in plasma. The sampling time points from pre-IV dose through 192 hours post-IV dose were used to assess this outcome.
| liter (L) | Part 2: LOXO-305 Oral Tablet + [14C]-LOXO-305 IV Solution |
|---|---|
| Part 2: PK: Volume of Distribution at Steady State (Vss) of [14C]-LOXO-305 in Plasma | 36.3 ± 24.2 |
CLR of \[14C\]-LOXO-305 in urine collection. The urine sampling time points from pre-IV dose through 192 hours post-IV dose were used to assess this outcome.
| liter per hour (L/h) | Part 2: LOXO-305 Oral Tablet + [14C]-LOXO-305 IV Solution |
|---|---|
| Part 2: PK: Renal Clearance (CLR) of [14C]-LOXO-305 | 0.116 ± 36.8 |
The urine sampling time points from pre-oral dose through 192 hours post-IV dose were used to assess this outcome.
| microgram (μg) | Part 2: LOXO-305 Oral Tablet + [14C]-LOXO-305 IV Solution |
|---|---|
| Part 2: PK: Cumulative Amount of [14C]-LOXO-305 Excreted in Urine | 1.59 ± 28.3 |
The urine sampling time points from pre-oral dose through 192 hours post-IV dose were used to assess this outcome.
| microgram equivalent (μg eq) | Part 2: LOXO-305 Oral Tablet + [14C]-LOXO-305 IV Solution |
|---|---|
| Part 2: PK: Cumulative Amount of Total Radioactivity Excreted in Urine | 14.1 ± 11.4 |
The Feces sampling time points from the 0 hour (i.e. time of oral dose) through 192 hours post-IV dose were used to assess this outcome.
| microgram (μg) | Part 2: LOXO-305 Oral Tablet + [14C]-LOXO-305 IV Solution |
|---|---|
| Part 2: PK: Cumulative Amount of [14C]-LOXO-305 Excreted in Feces | 3.02 ± 40.5 |
The Feces sampling time points from the 0 hour (i.e. time of oral dose) through 192 hours post-IV dose were used to assess this outcome.
| microgram equivalent (μg eq) | Part 2: LOXO-305 Oral Tablet + [14C]-LOXO-305 IV Solution |
|---|---|
| Part 2: PK: Cumulative Amount of Total Radioactivity Excreted in Feces | 4.97 ± 38.4 |
The urine sampling time points from pre-oral dose through 192 hours post-IV dose were used to assess this outcome.
| percentage of [14C]-LOXO-305 | Part 2: LOXO-305 Oral Tablet + [14C]-LOXO-305 IV Solution |
|---|---|
| Part 2: PK: Mean Cumulative Percentage of [14C]-LOXO-305 Excreted in Urine | 7.12 ± 28.9 |
The urine sampling time points from pre-oral dose through 192 hours post-IV dose were used to assess this outcome.
| percentage of total radioactivity | Part 2: LOXO-305 Oral Tablet + [14C]-LOXO-305 IV Solution |
|---|---|
| Part 2: PK: Mean Cumulative Percentage of Total Radioactivity Excreted in Urine | 63.1 ± 11.2 |
The Feces sampling time points from the 0 hour (i.e. time of oral dose) through 192 hours post-IV dose were used to assess this outcome.
| percentage of [14C]-LOXO-305 | Part 2: LOXO-305 Oral Tablet + [14C]-LOXO-305 IV Solution |
|---|---|
| Part 2: PK: Mean Cumulative Percentage of [14C]-LOXO-305 Excreted in Feces | 13.5 ± 40.5 |
The Feces sampling time points from the 0 hour (i.e. time of oral dose) through 192 hours post-IV dose were used to assess this outcome.
| percentage of total radioactivity | Part 2: LOXO-305 Oral Tablet + [14C]-LOXO-305 IV Solution |
|---|---|
| Part 2: PK: Mean Cumulative Percentage of Total Radioactivity Excreted in Feces | 22.3 ± 38.8 |
Collected over Part 1: Baseline up to Day 29; Part 2: Baseline up to Day 16. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part 1: [14C]-LOXO-305 Oral Solution | 0/4 (0%) | 0/4 (0%) | 3/4 (75%) |
| Part 2: LOXO-305 Oral Tablet + [14C]-LOXO-305 IV Solution | 0/5 (0%) | 0/5 (0%) | 4/5 (80%) |
| Event | Part 1: [14C]-LOXO-305 Oral Solution | Part 2: LOXO-305 Oral Tablet + [14C]-LOXO-305 IV Solution |
|---|---|---|
| Post procedural contusionInjury, poisoning and procedural complications | 0/4 | 3/5 |
| Procedural painInjury, poisoning and procedural complications | 0/4 | 2/5 |
| DiarrhoeaGastrointestinal disorders | 1/4 | 1/5 |
| Skin abrasionInjury, poisoning and procedural complications | 1/4 | 0/5 |
| HeadacheNervous system disorders | 1/4 | 0/5 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 1/4 | 0/5 |
| PapuleSkin and subcutaneous tissue disorders | 1/4 | 0/5 |
| Skin lacerationInjury, poisoning and procedural complications | 0/4 | 1/5 |
| Heart rate increasedInvestigations | 0/4 | 1/5 |
All enrolled participants.
| Age, Continuous(years) | Part 1: [14C]-LOXO-305 Oral Solution | Part 2: LOXO-305 Oral Tablet + [14C]-LOXO-305 IV Solution | Total |
|---|---|---|---|
| Mean | 39.5 ± 3.42 | 24 ± 5.15 | 30.9 ± 9.18 |
| Sex: Female, Male(Participants) | Part 1: [14C]-LOXO-305 Oral Solution | Part 2: LOXO-305 Oral Tablet + [14C]-LOXO-305 IV Solution | Total |
|---|---|---|---|
| Female | 0 | 0 | 0 |
| Male | 4 | 5 | 9 |
| Ethnicity (NIH/OMB)(Participants) | Part 1: [14C]-LOXO-305 Oral Solution | Part 2: LOXO-305 Oral Tablet + [14C]-LOXO-305 IV Solution | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 1 | 1 |
| Not Hispanic or Latino | 4 | 4 | 8 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Part 1: [14C]-LOXO-305 Oral Solution | Part 2: LOXO-305 Oral Tablet + [14C]-LOXO-305 IV Solution | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 1 | 1 |
| White | 3 | 4 | 7 |
| More than one race | 1 | 0 | 1 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Part 1: [14C]-LOXO-305 Oral Solution | Part 2: LOXO-305 Oral Tablet + [14C]-LOXO-305 IV Solution | Total |
|---|---|---|---|
| United States | 4 | 5 | 9 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Sep 2020 to primary completion in Nov 2020, 1 month.
Results were first posted in Jan 2025, 4 years 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pirtobrutinib